Myriad Genetics, Inc.

Myriad Genetics, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Myriad Genetics, Inc. has 95.60M shares outstanding.

As of June 30, 2026, Myriad Genetics, Inc. maintains a current ratio of 2.21, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 69.27, indicating elevated leverage, while an interest coverage ratio of -2.95 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. posted a negative return on equity (ROE) of -32.54, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.11, reflecting losses generated across the asset base. The company generates approximately 261,487.77 in revenue per employee across its workforce of 2,700.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.48 indicates how many times Myriad Genetics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. recorded 700,240.00 in income tax expense. The company reported a pretax loss of -97.86M and -98.56M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Myriad Genetics, Inc.'s stock has declined approximately 81.91% over the past 52 weeks. The 50-day moving average sits at 19.68, while the 200-day moving average is 23.68.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. generated 706.02M in revenue and converted that into -98.56M in net income, yielding earnings per share of -1.05. EBITDA reached -42.36M, while operating income came in at -79.21M.

As of June 30, 2026, Myriad Genetics, Inc. holds 100.83M in cash and equivalents against 184.25M in total debt, resulting in a net debt position of 4.81M. Total book value stands at 266.00M, with working capital of 138.56M providing operational flexibility.

Myriad Genetics, Inc. produced 6.74M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Myriad Genetics, Inc. posted a gross margin of 68.83, reflecting its pricing power and cost economics. The operating margin of -11.22 and net profit margin of -13.96 provide insight into operational efficiency.

Myriad Genetics, Inc.'s most recent stock split took place on March 26, 2009 with a 1:2 split ratio.